Most-Downgraded Stocks NASDAQ:FATE Fate Therapeutics - FATE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.87 +0.04 (+0.59%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$6.40▼$6.9550-Day Range$4.24▼$20.9152-Week Range$4.02▼$43.12Volume3.28 million shsAverage Volume5.13 million shsMarket Capitalization$667.56 millionP/E RatioN/ADividend YieldN/APrice Target$29.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Fate Therapeutics MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside333.0% Upside$29.75 Price TargetShort InterestHealthy16.92% of Float Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.53Based on 10 Articles This WeekInsider TradingAcquiring Shares$698,138 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.22) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.81 out of 5 starsMedical Sector27th out of 1,028 stocksBiological Products, Except Diagnostic Industry5th out of 168 stocks 4.1 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 6 buy ratings, 14 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.75, Fate Therapeutics has a forecasted upside of 333.0% from its current price of $6.87.Amount of Analyst CoverageFate Therapeutics has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.92% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Fate Therapeutics has recently decreased by 30.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 3.1 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search Interest25 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 127% compared to the previous 30 days.MarketBeat Follows17 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 113% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have bought 75.98% more of their company's stock than they have sold. Specifically, they have bought $698,138.00 in company stock and sold $396,710.00 in company stock.Percentage Held by Insiders17.34% of the stock of Fate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to grow in the coming year, from ($3.22) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fate Therapeutics (NASDAQ:FATE) StockFate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.Read More Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Stock News HeadlinesJanuary 25, 2023 | marketbeat.comHow Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (FATE)Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.January 18, 2023 | marketbeat.comJohnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock? (FATE)Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.February 4, 2023 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $26.14 Consensus Price Target from BrokeragesFebruary 3, 2023 | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) & Harpoon Therapeutics (NASDAQ:HARP) Critical SurveyFebruary 2, 2023 | benzinga.comCLASS ACTION UPDATE for GPS, FXLV and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersFebruary 2, 2023 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $26.14 Consensus Target Price from BrokeragesFebruary 1, 2023 | benzinga.comCLASS ACTION UPDATE for FXLV, FATE and EYE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 31, 2023 | benzinga.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the FirmJanuary 30, 2023 | technews.tmcnet.comNOTICE: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATEJanuary 30, 2023 | finance.yahoo.comCalculating The Fair Value Of Fate Therapeutics, Inc. (NASDAQ:FATE)January 28, 2023 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) to Post Q1 2023 Earnings of ($0.59) Per Share, HC Wainwright ForecastsJanuary 27, 2023 | benzinga.comFate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Fate Therapeutics, Inc.January 27, 2023 | benzinga.comROSEN, A LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATEJanuary 26, 2023 | benzinga.comINVESTOR ALERT: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATEJanuary 26, 2023 | benzinga.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)January 26, 2023 | americanbankingnews.comHC Wainwright Downgrades Fate Therapeutics (NASDAQ:FATE) to NeutralJanuary 25, 2023 | wsj.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the FirmJanuary 25, 2023 | wsj.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the FirmJanuary 24, 2023 | technews.tmcnet.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the FirmJanuary 24, 2023 | technews.tmcnet.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) InvestorsJanuary 24, 2023 | businesswire.comShareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)January 24, 2023 | markets.businessinsider.comAnalyst Ratings for Fate TherapeuticsJanuary 23, 2023 | technews.tmcnet.comKirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) InvestorsJanuary 23, 2023 | technews.tmcnet.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) InvestorsJanuary 23, 2023 | wsj.comFate Therapeutics Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More InformationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Company Calendar Last Earnings11/04/2021Today2/05/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees449Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.75 High Stock Price Forecast$90.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+333.0%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,150,000.00 Net Margins-425.99% Pretax Margin-425.99% Return on Equity-48.78% Return on Assets-35.25% Debt Debt-to-Equity RatioN/A Current Ratio5.15 Quick Ratio5.15 Sales & Book Value Annual Sales$55.85 million Price / Sales11.95 Cash FlowN/A Price / Cash FlowN/A Book Value$7.11 per share Price / Book0.97Miscellaneous Outstanding Shares97,170,000Free Float80,321,000Market Cap$667.56 million OptionableOptionable Beta1.46 Key ExecutivesJ. Scott WolchkoPresident, Chief Executive Officer & DirectorEdward J. DulacChief Financial Officer & Accounting OfficerBahram ValamehrChief Research & Development OfficerWen Bo WangSenior Vice President-Technical OperationsYu Waye ChuChief Medical OfficerKey CompetitorsScholar RockNASDAQ:SRRKImmaticsNASDAQ:IMTXPoseida TherapeuticsNASDAQ:PSTXHilleVaxNASDAQ:HLVXSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsMach 1 Financial Group LLCBought 51,574 shares on 2/2/2023Ownership: 0.053%AtonRa PartnersSold 4,034 shares on 2/2/2023Ownership: 0.015%Simplex Trading LLCSold 2,100 shares on 2/2/2023Ownership: 0.000%State of New Jersey Common Pension Fund DBought 39,324 shares on 2/1/2023Ownership: 0.122%Zurcher Kantonalbank Zurich Cantonalbank Bought 4,685 shares on 2/1/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions FATE Stock - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 sell ratings, 14 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price forecast for 2023? 22 Wall Street analysts have issued 1-year price targets for Fate Therapeutics' shares. Their FATE share price forecasts range from $7.00 to $90.00. On average, they expect the company's share price to reach $29.75 in the next year. This suggests a possible upside of 333.0% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2023? Fate Therapeutics' stock was trading at $10.09 at the beginning of 2023. Since then, FATE shares have decreased by 31.9% and is now trading at $6.87. View the best growth stocks for 2023 here. Are investors shorting Fate Therapeutics? Fate Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 15,450,000 shares, a decline of 30.8% from the December 31st total of 22,330,000 shares. Based on an average daily trading volume, of 3,130,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 16.9% of the company's shares are short sold. View Fate Therapeutics' Short Interest. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.13. The biopharmaceutical company had revenue of $14.23 million for the quarter, compared to analyst estimates of $8.67 million. Fate Therapeutics had a negative net margin of 425.99% and a negative trailing twelve-month return on equity of 48.78%. The firm's revenue was up 88.3% on a year-over-year basis. During the same period last year, the firm earned ($0.36) EPS. What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (4.34%), Sumitomo Mitsui Trust Holdings Inc. (0.93%), Monaco Asset Management SAM (0.26%), Rice Hall James & Associates LLC (0.22%), Comerica Bank (0.14%) and State of New Jersey Common Pension Fund D (0.12%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $6.87. How much money does Fate Therapeutics make? Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $667.56 million and generates $69.01 million in revenue each year. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. How many employees does Fate Therapeutics have? The company employs 449 workers across the globe. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com. This page (NASDAQ:FATE) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.